Clinical trials

  • Interventional, randomized, double-blind, parallel-group, placebo-controlled study of add-on eptinezumab treatment to brief educational intervention for the preventive treatment of migraine in patients with dual diagnosis of migraine and medication overuse headache. EudraCT Number 2021-003049-40. Role: Local PI. Sponsor institution: H. Lundbeck A/S.
  • CandMig 3 Study - Candesartan for migraine prevention: A multicentre, binational, triple blind, placebo controlled, parallel group study of two doses of candesartan (8 and 16 mg). EudraCT Number 2019-003386-18. Role: Local PI. Sponsor institution: St. Olav’s Hospital, Trondheim.
  • MiBlock Study - Botulinum toxin type A blockade of the sphenopalatine ganglion in treatmentrefractory chronic migraine: A randomized, placebo-controlled, triple-blind (blinded statistician), multicentre, parallel group proof-of-concept, phase 3 study. EudraCT Number 2018-004053-24. Role: Sub-PI. Sponsor institution: St. Olav’s Hospital and NTNU, Trondheim.
  • AIM Study - Efficacy of antibiotic treatment in patients with chronic low back pain and Modic changes: A double blind, randomised, placebo controlled, multicentre trial Role: Sub-PI. Sponsor institution: OUH.
 
Scroll to top